Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public Support. Subtract line 5 from line 4. | ||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | ||||||
| 11 | Total support (Add lines 7 through 10). | ||||||






| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Multi-disciplinary Centre of Oncology, Lausanne, Switzerland. University Clinic of St. Luc, Brussels, Belgium. The Royal Melbourne Hospital, Melbourne, Australia. Austin Health, Melbourne, Australia. Alemao Oswaldo Cruz, Sao Paulo, Brazil. Karolinska Universitetssjukhuset, Stockholm, Sweden. Akademiska Sjukhuset, Uppsala, Sweden. Memorial Sloan-Kettering Cancer Center, New York. University of California, San Diego - School of Medicine, San Diego. Krankenhaus Nordwest, Frankfurt am Main, Germany. Universitatsspital Zurich, Zurich, Switzerland. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 990, PART III | LABORATORY RESEARCH LEADING TO CLINICAL APPLICATIONS - LINE 4A THE PROSPECTS FOR CONTROLLING CANCER WILL ONLY IMPROVE THROUGH AN ONGOING COMMITMENT TO INNOVATIVE RESEARCH THAT HAS A SINGULAR FOCUS ON THE UNDERSTANDING OF CANCER ONSET AND PROGRESSION, AND THE IDENTIFICATION AND CHARACTERIZATION OF TOOLS AND TARGETS FOR NEW PROGNOSTIC, DIAGNOSTIC AND THERAPEUTIC MODALITIES. THE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (LICR) ENGAGES LEADING SCIENTISTS AND CLINICIANS IN AN INTEGRATED LABORATORY AND CLINICAL RESEARCH EFFORT TO UNDERSTAND AND CONFRONT THE GLOBAL CHALLENGE OF CANCER. LICR LABORATORY RESEARCH SEEKS TO EXTEND ITS KNOWLEDGE OF GENES, PROTEINS, CELLS AND CELLULAR PROCESSES INVOLVED IN CANCER ONSET AND PROGRESSION. THIS UNDERSTANDING OF THE MACROMOLECULAR AND CELLULAR ABERRATIONS IN CANCER THEN ALLOWS LICR INVESTIGATORS TO FURTHER THEIR LABORATORY WORK TO IDENTIFY, CHARACTERIZE AND TEST NEW TOOLS AND TARGETS FOR THEIR POTENTIAL AS CLINICAL APPLICATIONS. SUBSTANTIALLY ALL LABORATORY RESEARCH FINANCED BY LICR IS CARRIED OUT BY THE INSTITUTE'S OWN APPOINTED RESEARCH STAFF OR THROUGH RESEARCH COLLABORATIONS INVOLVING LICR STAFF AND EXTERNAL INVESTIGATORS. THE RESEARCH STAFFS OF THE INSTITUTE WERE ORGANIZED IN BRANCHES WITH ONE BRANCH EACH IN BELGIUM, BRAZIL, SWITZERLAND AND THE UK, AND TWO EACH IN AUSTRALIA, SWEDEN AND THE USA. THE INSTITUTE EMPLOYED AROUND 730 SCIENTISTS, CLINICIANS AND SUPPORT PERSONNEL AT DECEMBER 31, 2010, WITH EACH BRANCH STAFFED TO ENSURE THAT COMPLEX CANCER RESEARCH PROBLEMS CAN BE ADDRESSED BY A CRITICAL MASS OF INVESTIGATORS HAVING EXPERTISE IN SEVERAL SCIENTIFIC DISCIPLINES. THE BRANCHES HAVE BEEN ESTABLISHED IN ASSOCIATION WITH A LEADING NON-PROFIT UNIVERSITY, HOSPITAL AND/OR RESEARCH INSTITUTE TO FACILITATE CLOSE COLLABORATION BETWEEN LABORATORY AND CLINICAL SCIENTISTS AND TO PROVIDE ACCESS TO THE WIDEST RANGE OF SCIENTIFIC, TECHNOLOGICAL AND CLINICAL RESOURCES. DURING 2010, THE INSTITUTE OPERATED TEN BRANCHES IN SEVEN COUNTRIES IN AUSTRALASIA, EUROPE, AND NORTH AND SOUTH AMERICA, AND WORKED ON COLLABORATIVE PROGRAMS WITH NUMEROUS AFFILIATES IN OTHER COUNTRIES. A LIMITATION OF THE ACADEMIC MEDICAL RESEARCH-IN WHICH FUNDING IS GIVEN TO INDIVIDUAL INVESTIGATORS BY GOVERNMENT AGENCIES AND NOT THE INVESTIGATOR'S ACADEMIC INSTITUTION-IS THAT RESEARCH PROJECTS ARE TOO FREQUENTLY FRAGMENTED, OVERLAPPING, AND LACKING IN STRATEGIC COORDINATION. RESEARCH ALSO BECOMES PREDOMINANTLY DEFINED BY WHAT CAN BE ACHIEVED IN A SINGLE LABORATORY WITHIN A FUNDING CYCLE OF, TYPICALLY, THREE YEARS. IN CONTRAST, LICR FUNDS 60% OF THE COST OF THE RESEARCH THAT IT CONDUCTS, SUPPORT THAT IS DRAWN FROM THE INSTITUTE'S SEPARATELY HELD INVESTMENT PORTFOLIO. THIS RELIABLE AND FLEXIBLE FUNDING MODEL GIVES LICR INVESTIGATORS THE FREEDOM TO TACKLE SPECULATIVE, LONG-TERM RESEARCH, AND ENCOURAGES AND ENABLES MULTIDISCIPLINARY TEAMS OF INVESTIGATORS TO TACKLE LARGER, MORE COMPLEX CANCER CHALLENGES. A VAST AMOUNT OF OUR UNDERSTANDING ABOUT CANCER HAS COME FROM THE DETAILED AND SYSTEMATIC ANALYSIS OF THE STRUCTURE, FUNCTION AND RELATIONSHIPS OF SINGLE MOLECULES. ALTHOUGH THERE IS STILL MUCH TO BE LEARNED FROM THIS APPROACH, LICR BELIEVES IT IS IMPERATIVE TO ALSO UNDERTAKE CELLULAR AND CLINICAL STUDIES OF THE HUMAN DISEASE IN ORDER TO MAKE CONTINUED AND SUBSTANTIVE PROGRESS IN OUR UNDERSTANDING AND CONTROL OF CANCER. WE NOW KNOW THAT THE TERM "CANCER" ENCOMPASSES A RANGE OF DIFFERENT DISEASES, AND THAT THERE CAN BE SUBSTANTIAL DIFFERENCES IN DISEASE PROGRESSION AND/OR TREATMENT RESPONSE BETWEEN INDIVIDUALS WITH ANY ONE TYPE OF CANCER. WE ALSO NOW KNOW THAT TUMORS ARE COMPOSED OF MULTIPLE, WHOLE HUMAN CELLS AND MUST BE CONSIDERED AS ORGANS HAVING THEIR OWN TISSUE STRUCTURE AND ENVIRONMENT. THUS LICR AIMS TO INTEGRATE STUDIES TAKING THESE FACTORS INTO ACCOUNT THROUGH ACCESSING CLINICAL SPECIMENS. IN ORDER TO FULFILL ITS MISSION TO IMPROVE BOTH THE UNDERSTANDING AND CONTROL OF CANCER, LICR IS COMMITTED TO SEEKING TO EXPLOIT NEW KNOWLEDGE FOR IMPROVED CLINICAL CARE. THIS IS DONE BY DEVELOPING EXPERIMENTAL THERAPEUTIC AGENTS AND BIOMARKERS BASED ON NOVEL EXPERIMENTAL FINDINGS. THE THERAPEUTIC AGENTS CAN BE SMALL MOLECULE INHIBITORS, TUMOR-TARGETING ANTIBODIES OR IMMUNOMODULATORY CANCER VACCINES. THESE ARE USED BOTH TO ENHANCE DISCOVERY-ORIENTED RESEARCH AND TO PROBE CLINICAL UTILITY. THE PROTECTION AND LICENSING OF INTELLECTUAL PROPERTY (IP) GENERATED BY RESEARCH DISCOVERIES AND TECHNOLOGY DEVELOPMENT IS FUNDAMENTAL TO LICR'S COMMITMENT TO TRANSLATE ITS DISCOVERIES INTO APPLICATIONS FOR HUMAN BENEFIT. WITHOUT A PROPRIETARY POSITION, FOR-PROFIT COMPANIES WILL NOT INVEST IN THE CLINICAL DEVELOPMENT, MANUFACTURE, DISTRIBUTION, MARKETING AND SALES REQUIRED TO TRANSLATE LICR DISCOVERIES INTO NEW THERAPIES FOR CANCER PATIENTS. ACCORDINGLY, LICR PATENTS ITS DISCOVERIES SUCH THAT ITS IP IS MANAGED FOR PUBLIC BENEFIT; THE IP IS MADE FREELY-AVAILABLE TO THE ACADEMIC RESEARCH COMMUNITY, AND A FINANCIAL RETURN CAN BE EXPECTED FOR THE COMPANY THAT INVESTS IN THE THERAPY'S SUCCESSFUL DEVELOPMENT AND, POTENTIALLY, FOR LICR TO FUND FURTHER RESEARCH EFFORTS. IN 2010, LICR INVESTIGATORS PUBLISHED 314 PRIMARY RESEARCH ARTICLES AND 54 REVIEWS, BOOK CHAPTERS AND/OR COMMENTARIES. THESE PUBLICATIONS COVERED A RANGE OF CANCER RESEARCH DISCOVERIES IN THE FIELDS OF GENETICS, GENOMICS, CELL BIOLOGY, SIGNAL TRANSDUCTION, PROTEOMICS, IMMUNOLOGY, BIOINFORMATICS, AND TARGETED THERAPY DEVELOPMENT. IN 2010, 14 PATENTS WERE ISSUED AND 25 WERE FILED IN THE USA BASED ON LICR DISCOVERIES, AND A FURTHER 6 NEW INTERNATIONAL PATENT APPLICATIONS WERE FILED AS WELL. THESE PATENTS COVER RESEARCH DISCOVERIES RELATING TO GROWTH FACTORS, CYTOKINES, SIGNALING MOLECULES, ANTIBODIES AND HUMAN TUMOR ANTIGENS. CLINICAL RESEARCH - LINE 4B LABORATORY RESEARCH ON ISOLATED CELLS AND MACROMOLECULES WILL NOT ALONE PRODUCE THE DIAGNOSTIC AND THERAPEUTIC MODALITIES REQUIRED FOR CANCER CONTROL. TO FURTHER UNDERSTAND THE DISEASE AND THE BODY'S REACTION TO IT, AND TO EXPLORE THE THERAPEUTIC POTENTIAL OF DISCOVERIES, CLINICAL RESEARCH-THE ANALYSIS OF PATIENT SAMPLES AND POTENTIAL THERAPIES IN CLINICAL TRIALS-MUST ALSO BE CONDUCTED. RECOGNIZING THIS, LICR TAKES RESPONSIBILITY FOR THE ENTIRE DISCOVERY CONTINUUM, FROM THE LABORATORY TO THE CLINIC. MANY UNIVERSITIES AND ACADEMIC RESEARCH INSTITUTES LACK THE EXPERTISE, INFRASTRUCTURE AND RESOURCES TO INTRODUCE THEIR LABORATORY DISCOVERIES INTO THE CLINIC. TO BRIDGE THAT DIVIDE THEY TURN THEIR WORK PRODUCT OVER TO COMPANIES THAT ENGAGE IN DRUG DEVELOPMENT, A PROCESS DRIVEN BY PRIMARILY COMMERCIAL CONSIDERATIONS: TIME TO PRODUCT LAUNCH AND SHARE OF MARKET CAPTURED. BETWEEN THE WORLDS OF LABORATORY DISCOVERY AND THERAPEUTIC UTILITY, THERE IS A MISSING LINK THAT INTERRUPTS THE EFFICIENT EXPLORATION OF KNOWLEDGE FOR HUMAN BENEFIT. THAT MISSING LINK IS CLINICAL RESEARCH. LICR IS CONVINCED THAT THE SAME SYSTEMATIC, INVESTIGATIVE RIGOR THAT YIELDED THE LABORATORY DISCOVERY IN THE FIRST PLACE SHOULD BE APPLIED IN EARLY-PHASE CLINIC TRIALS TO ASSESS A DISCOVERY'S THERAPEUTIC POTENTIAL. THE INSTITUTE HAS, THEREFORE, COMMITTED THE RESOURCES AND MARSHALLED THE CAPABILITIES THAT ALLOW IT TO EVALUATE ITS PROMISING BASIC DISCOVERIES IN FIRST-IN-MAN CLINICAL STUDIES. LICR HAS LICENSING INTERACTIONS WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES THAT ALLOW THE INSTITUTE TO OBTAIN PROPRIETARY INVESTIGATIONAL AGENTS AND CLINICALLY EVALUATE WHETHER THESE AGENTS MIGHT COMPLEMENT THE THERAPEUTIC POTENTIAL OF THE INSTITUTE'S OWN DISCOVERIES. LICR'S INTERACTIONS WITH INDUSTRY ARE DESIGNED TO PROTECT THE ETHOS AND INTEGRITY OF THE INSTITUTE AND TO ENSURE THAT ITS DISCOVERIES ARE ACTIVELY PURSUED AS PROGNOSTIC, DIAGNOSTIC AND/OR THERAPEUTIC AGENTS FOR HUMAN BENEFIT. SEVENTEEN INSTITUTE-SPONSORED CLINICAL TRIALS WERE ONGOING IN 2010. FOUR ADDITIONAL STUDIES WERE MANAGED BY THE INSTITUTE, BUT NOT SPONSORED DIRECTLY. INSTITUTE INVESTIGATIONAL STUDY AGENTS WERE PROVIDED FOR AN ADDITIONAL 8 CLINICAL TRIALS SPONSORED AND MANAGED BY LOCAL ENTITIES. THESE 29 TRIALS WERE SUPPORTED BY 13 ACTIVE INSTITUTE REGULATORY DOSSIERS [9 INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS (USA), 2 DRUG MASTER FILES (DMF) AND 2 INVESTIGATIONAL MEDICINAL PRODUCT DOSSIERS, (EUROPEAN UNION)]. OVER THE YEAR THE INSTITUTE MADE 25 SUPPLEMENTAL SUBMISSIONS TO ITS ACTIVE REGULATORY DOSSIERS. | |
| FORM 990, PARTS IV, LINE 12A AND XII, LINE 1 | THE INSTITUTE PREPARED CONSOLIDATED FINANCIAL STATEMENTS IN ACCORDANCE WITH SWISS GAAP FER. THE INSTITUTE PREPARED STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE INSTITUTE PREPARED BRANCH FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS FOR THE FOLLOWING BRANCHES: BRUSSELS (BELGIUM), LAUSANNE (SWITZERLAND), MELBOURNE-PARKVILLE (AUSTRALIA), MELBOURNE-AUSTIN (AUSTRALIA), OXFORD (UNITED KINGDOM), NEW YORK AND SAN DIEGO (UNITED STATES), SAO PAULO (BRAZIL), STOCKHOLM AND UPPSALA (SWEDEN). THE SUBMITTED RETURN 990 IS BASED ON THE STATUTORY FINANCIAL STATEMENTS IN ACCORDANCE WITH THE SWISS CODE OF OBLIGATIONS. THE FOLLOWING ACCOUNTING PRINCIPLES APPLY: - CONTRIBUTIONS ARE ACCOUNTED FOR ON THE CASH BASIS - INTEREST IS ACCOUNTED FOR ON THE ACCRUAL BASIS - EXTERNAL FUNDING RECEIVED FROM ANY OUTSIDE SOURCE, WHETHER OF CASH OR A NON-CASH NATURE, IS RECORDED IN THE INSTITUTE'S BOOKS OF ACCOUNT ON RECEIPT. EXTERNAL FUNDING RECEIVED IS TAKEN TO INCOME WHEN THE CORRESPONDING EXPENDITURE IS INCURRED. ANY UNSPENT INCOME IS DEFERRED TO FUTURE ACCOUNTING PERIODS. EXTERNAL FUNDING PLEDGED, BUT NOT RECEIVED WHERE EXPENDITURE HAS BEEN INCURRED, IS TAKEN TO ACCOUNT AS INCOME AND IS ACCOUNTED FOR AS A GRANTS RECEIVABLE PENDING RECEIPT. - LICENCE FEES AND ROYALTIES ARE ACCOUNTED FOR ON THE MODIFIED CASH BASIS. - EXPENDITURE ON EQUIPMENT AND OTHER ASSETS AND LEASEHOLD IMPROVEMENTS IS CHARGED IN FULL AGAINST REVENUE IN THE YEAR IT IS INCURRED. THE INSTITUTE PREPARED BRANCH FINANCIAL STATEMENTS IN ACCORDANCE WITH LOCAL ACCOUNTING REQUIREMENTS FOR THE BRANCHES IN NEW YORK (UNITED STATES) AND SAO PAULO (BRAZIL). THE INSTITUTE PREPARED FINANCIAL STATEMENTS IN ACCORDANCE WITH OFFICE OF MANAGEMENT AND BUDGET CIRCULAR A-133 FOR THE SAN DIEGO BRANCH (UNITED STATES). THE INSTITUTE MAINTAINS ACCOUNTING LEDGERS BY CURRENCY, BY BRANCH, AND BY FUNCTION. INSTITUTE CURRENCIES ARE: AUD, BRL, CHF, EUR, GBP, SEK AND USD. WHEN ANY EXPENDITURE/INCOME OR BALANCE SHEET TRANSACTIONS ARE RECORDED INTO THE ACCOUNTS, A NON-INSTITUTE CURRENCY IS CONVERTED INTO AN INSTITUTE CURRENCY AMOUNT USING THE RATE RULING AT THE DATE OF THE TRANSACTION. FOR THE PRODUCTION OF THE STATUTORY FINANCIAL STATEMENTS DENOMINATED IN USD, THE FOLLOWING PRINCIPLES APPLY: NON-USD CONTRIBUTION INCOME IS TRANSLATED INTO USD AT THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. ALL OTHER NON-USD INCOME ITEMS ARE TRANSLATED INTO USD AT THE YEARLY AVERAGE OF THE MONTHLY RATES AS PUBLISHED BY THE SWISS TAX AUTHORITIES. NON-USD ASSETS AND LIABILITIES ARE TRANSLATED INTO USD AT THE RATES RULING AT THE END OF THE YEAR. THE RESULTING TRANSLATION ADJUSTMENTS ARE INCLUDED IN THE EXCESS OF EXPENDITURE OVER INCOME FOR THE YEAR. FORM 990, PART VI, SECTION A, LINE 2 BUSINESS: OLIVIER R.E. DUNANT AND ALFRED BERGER, DIRECTORS ON LUDWIG INSTITUTE FOR CANCER RESEARCH LTD'S BOARD, ALSO SERVE ON THE BOARD OF ANOTHER ORGANIZATION. BUSINESS: DR. ANDREW SIMPSON AND DR. JONATHAN SKIPPER, OFFICERS OF LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, SERVE ON THE BOARD OF ANOTHER ORGANIZATION. BUSINESS: EDWARD A. MCDERMOTT JR. AND DR. JONATHAN SKIPPER ARE OFFICERS OF A RELATED FOR PROFIT ORGANIZATION. | |
| FORM 990, PART VI, SECTION A, LINE 4 | ON JUNE 22, 2010 THE INSTITUTE'S BY-LAWS WERE AMENDED TO REFLECT THE FOLLOWING CHANGES IN MANAGEMENT STRUCTURE: 1) BOARD OF DIRECTORS - CONSTITUTION NEW PROVISION: THE BOARD OF DIRECTORS SHALL CONSIST OF AT LEAST THREE INDIVIDUALS AT LEAST ONE OF WHOM IS DOMICILED IN SWITZERLAND. EACH MEMBER OF THE BOARD MUST BE A SHAREHOLDER. INDIVIDUALS NOMINATED AND ELECTED TO THE BOARD SHALL BE DEDICATED TO THE MISSION OF THE INSTITUTE, POSSESS HIGH MORAL AND ETHICAL STANDARDS, HAVE THE REQUISITE EDUCATION AND EXPERIENCE TO MAKE A SIGNIFICANT CONTRIBUTION TO THE BOARD AND BRING A RANGE OF SKILLS, PERSPECTIVES AND BACKGROUNDS TO ITS DELIBERATIONS. 2) QUORUM, RESOLUTIONS AND RECORDS OF PROCEEDINGS CONCURRENCE OF THREE QUARTERS OF ALL MEMBERS OF THE BOARD OF DIRECTORS NOW ONLY REQUIRED FOR MATERIAL MATTERS OF POLICY AND PROCEDURE INCLUDING A) APPROVAL OF THE OPERATING BUDGET AND ANY INTERIM ADJUSTMENT; B) THE SALE OR OTHER DISPOSITION OF SUBSTANTIAL ASSETS OF THE INSTITUTE; C) SUBSTANTIAL CHANGE IN THE INVESTMENT AND HOLDING OF ASSETS; D) THE ADOPTION OR AMENDMENT OF BY-LAWS FOR THE CONDUCT OF THE AFFAIRS OF THE INSTITUTE; E) THE APPOINTMENT AND REMOVAL OF ANY OF THE EXECUTIVE OFFICERS OF THE INSTITUTE; F) A RECOMMENDATION FOR AMENDING THE STATUTES OF THE INSTITUTE; OR G) A CHANGE IN THE STRATEGIC APPROACH OR BRANCH STRUCTURE OF THE INSTITUTE. 3) NON-TRANSFERABLE AND IRREVOCABLE DUTIES OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ART. 716B OF THE SWISS CODE OF OBLIGATIONS: -THE DUTY TO DETERMINE THE ORGANIZATION NOW SPECIFICALLY REFERS TO THE ISSUANCE AND AMENDMENT OF THE BY-LAWS -A JUDGE IS TO BE INFORMED OF OVER INDEBTEDNESS -THE BOARD IS TO PASS RESOLUTIONS ON THE ADOPTION OF CAPITAL INCREASES AS LONG AS SUCH ACTION IS IN COMPLIANCE WITH ART. 651 PARA 4 OF SWISS CODE OF OBLIGATIONS. 4) DUTIES OF THE PRESIDENT THE PRESIDENT SHALL BE THE CHIEF EXECUTIVE OFFICER. 5) DUTIES OF THE EXECUTIVE OFFICERS THE POSITIONS OF EXECUTIVE DIRECTOR FOR LABORATORY SCIENCE AND TECHNOLOGY, EXECUTIVE DIRECTOR FOR CLINICAL AND TRANSLATIONAL RESEARCH AND EXECUTIVE DIRECTOR FOR PROGRAMS AND OPERATIONS WERE DISCONTINUED. THE NEW POSITION EXECUTIVE DIRECTOR OF OPERATIONS WAS CREATED WITH THE FOLLOWING DUTIES: TO ASSIST THE SCIENTIFIC DIRECTOR IN MANAGING THE SCIENTIFIC ADMINISTRATION, COORDINATING THE ORGANIZATIONAL INFRASTRUCTURE, OPTIMIZING OPERATIONAL EFFICIENCY AND ALONG WITH OTHER EXECUTIVE DIRECTORS, DEVELOPING AND EXECUTING STRATEGIC, SCIENTIFIC AND POLICY INITIATIVES. THE EXECUTIVE DIRECTOR OF OPERATIONS SHALL REPORT TO THE SCIENTIFIC DIRECTOR AND PERFORM SUCH OTHER DUTIES AS MAY BE PRESCRIBED FROM TIME TO TIME BY THE SCIENTIFIC DIRECTOR, PRESIDENT OR THE BOARD OF DIRECTORS. THE NEW POSITION EXECUTIVE DIRECTOR OF COLLABORATIVE SCIENCES WAS CREATED WITH THE FOLLOWING DUTIES: TO ASSIST THE SCIENTIFIC DIRECTOR IN COORDINATING INSTITUTE RESEARCH INITIATIVES, MANAGING SCIENTIFIC COLLABORATIONS, PURSUING EXTERNAL FUNDING OPPORTUNITIES IN SUPPORT OF INSTITUTE RESEARCH AND COLLABORATIONS, FACILITATING INTERACTIONS BETWEEN THE INSTITUTE AND LUDWIG CENTERS, AND ALONG WITH OTHER EXECUTIVE DIRECTORS, DEVELOPING AND EXECUTING STRATEGIC, SCIENTIFIC AND POLICY INITIATIVES. THE EXECUTIVE DIRECTOR OF COLLABORATIVE SCIENCES SHALL REPORT TO THE SCIENTIFIC DIRECTOR AND PERFORM SUCH OTHER DUTIES AS MAY BE PRESCRIBED FROM TIME TO TIME BY THE SCIENTIFIC DIRECTOR, PRESIDENT OR THE BOARD OF DIRECTORS. THE POSITION OF EXECUTIVE DIRECTOR FOR INTELLECTUAL PROPERTY AND LICENSING WAS RE-TITLED TO EXECUTIVE DIRECTOR OF TECHNOLOGY DEVELOPMENT WITH THE FOLLOWING NEW DUTIES: TO ASSIST THE SCIENTIFIC DIRECTOR IN ADMINISTERING THE INTELLECTUAL PROPERTY OF THE INSTITUTE, OVERSEEING THE DEVELOPMENT OF PROMISING CLINICAL CANDIDATES, NEGOTIATING INTER-INSTITUTIONAL COLLABORATIONS, AND MANAGING COMMERCIAL LICENSE ARRANGEMENTS AND ALONG WITH OTHER EXECUTIVE DIRECTORS, DEVELOPING AND EXECUTING STRATEGIC, SCIENTIFIC AND POLICY INITIATIVES. THE EXECUTIVE DIRECTOR FOR TECHNOLOGY DEVELOPMENT SHALL REPORT TO THE SCIENTIFIC DIRECTOR AND PERFORM SUCH OTHER DUTIES AS MAY BE PRESCRIBED FROM TIME TO TIME BY THE SCIENTIFIC DIRECTOR, PRESIDENT OR THE BOARD OF DIRECTORS. THE DUTIES OF THE CHIEF FINANCIAL OFFICER WERE EXPANDED TO INCLUDE "WITH THE PRESIDENT DEVELOPING AND IMPLEMENTING STRATEGIC AND POLICY INITIATIVES". THE SCIENTIFIC ADVISORY COMMITTEE SHALL BE (NEW) APPOINTED AND THEIR TERMS OF ENGAGEMENT SET BY THE SCIENTIFIC DIRECTOR IN CONSULTATION WITH THE PRESIDENT AND THE EXECUTIVE DIRECTORS. THEIR DUTY IS TO ADVISE ON THE SCIENTIFIC MISSION, POLICIES (INCLUDING, THE APPOINTMENT AND SUCCESSION OF THE BRANCH DIRECTORS AND OTHER SCIENTIFIC AND CLINICAL PERSONNEL), THE OPERATION OF THE RESEARCH AND THE DEVELOPMENT OF THE TECHNOLOGY OF THE INSTITUTE. | |
| FORM 990, PART VI, SECTION A, LINE 6 | THE INSTITUTE IS ORGANIZED AS A SWISS NOT-FOR-PROFIT ORGANIZATION. FORTY-NINE OF THE SHARES ARE HELD BY THE TRUSTEES OF THE LICR CHARITABLE TRUST, A BERMUDA TRUST RECOGNIZED BY THE IRS AS AN EXEMPT SUPPORTING ORGANIZATION OF THE INSTITUTE UNDER SECTIONS 501(C)(3) AND 509(A)(3) OF THE INTERNAL REVENUE CODE, WHOSE PRIMARY PURPOSE IS TO ADMINISTER, DEVOTE AND APPLY ITS TRUST ESTATE TO FURTHER THE CHARITABLE AND SCIENTIFIC PURPOSES OF THE INSTITUTE. OF THE FORTY-NINE SHARES HELD BY THE TRUSTEES OF THE LICR CHARITABLE TRUST, THERE ARE THIRTY-EIGHT SCHEDULE A SHARES AND ELEVEN SCHEDULE B SHARES. FOLLOWING THE PROVISIONS OF THE INSTITUTE'S STATUTES, MEMBERS OF THE BOARD OF DIRECTORS ARE REQUIRED TO BE SHAREHOLDERS. THE ELEVEN SCHEDULE B SHARES ARE AVAILABLE FOR THIS PURPOSE AND DURING THE MEMBER OF THE BOARDS' TENURE, THE TRUSTEES OF THE LICR CHARITABLE TRUST ASSIGNS TO EACH BOARD MEMBER ONE SHARE. THE INSTITUTE'S OTHER OUTSTANDING SHARE IS HELD BY THE SWISS CONFEDERATION. FORM 990, PART VI, SECTION A, LINE 7A THE STATUTES OF THE INSTITUTE CONFER ON ITS SHAREHOLDERS THE AUTHORITY TO ELECT AND REMOVE MEMBERS OF THE BOARD OF DIRECTORS AND PARTICIPATE IN PROCEEDINGS, DELIBERATIONS, ELECTIONS AND VOTES AT SHAREHOLDER MEETINGS. THE SHARES DO NOT CONFER PROPRIETARY RIGHTS OR ANY ENTITLEMENT TO ANY SHARE OF THE INSTITUTE'S NET INCOME OR CAPITAL OR ANY OTHER ASSETS OWNED OR MANAGED BY THE INSTITUTE. THE INSTITUTE'S STATUTES PROHIBIT THE PAYMENT OF ANY DIVIDENDS OR DISTRIBUTION OF INCOME OR CAPITAL TO THE SHAREHOLDERS. FORM 990, PART VI, SECTION A, LINE 7B THE SHAREHOLDERS HAVE THE POWERS TO GRANT DISCHARGE TO THE MEMBERS OF THE BOARD OF DIRECTORS ANNUALLY AT THE SHAREHOLDERS ANNUAL MEETING FOR THEIR CONDUCT OF INSTITUTE BUSINESS. THE ANNUAL REPORT AND ANNUAL FINANCIAL STATEMENTS ARE SUBMITTED TO THE SHAREHOLDERS BY THE BOARD OF DIRECTORS FOR SHAREHOLDER APPROVAL. THE SHAREHOLDERS HAVE THE RIGHT TO MAKE RESOLUTIONS IN RESPECT OF MERGERS, DISSOLUTIONS OR LIQUIDATION OF THE COMPANY AND OF ANY CHANGE OF THE COMPANY'S REGISTERED OFFICE. FORM 990, PART VI, SECTION B, LINE 11B THE INSTITUTE'S FORM 990 IS REVIEWED AT SEVERAL LEVELS. THE INSTITUTE'S ZURICH OFFICE SENIOR STAFF, THE DIRECTOR OF TAXES LOCATED IN NEW YORK, AND EXTERNAL TAX AND LEGAL COUNSEL REVIEW THE DRAFT FORM 990. FOLLOWING THESE REVIEWS, THE CHAIRMAN OF THE AUDIT COMMITTEE REVIEWS THE DRAFT RETURN PRIOR TO PRESENTING IT TO THE AUDIT COMMITTEE FOR FURTHER REVIEW. THE DRAFT FORM 990 IS THEN PRESENTED TO THE INSTITUTE'S BOARD OF DIRECTORS PRIOR TO ITS SUBMISSION TO THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ANNUALLY, ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS AND ALL STAFF ARE REQUIRED TO DISCLOSE ANY CONFLICTS OF INTEREST BY COMPLETING A QUESTIONNAIRE. IN ADDITION, INDIVIDUALS ARE REQUIRED TO REPORT ANY CONFLICTS AS THEY ARISE DURING THE YEAR. THE COMPLETED QUESTIONNAIRES OF THE MEMBERS OF THE BOARD OF DIRECTORS AND OFFICERS ARE REVIEWED BY THE COMPLIANCE AND RISK OFFICER AND THE CHAIRMAN OF THE AUDIT COMMITTEE AND THEIR WORK THEREON IS REPORTED TO THE AUDIT COMMITTEE. IF A CONFLICT OF INTEREST IS DEEMED TO EXIST, IT IS THE DUTY OF THE INDIVIDUAL WITH THE CONFLICT TO DISCLOSE IT. THE INTEREST IS RECORDED IN THE MINUTES OF THE MEETING OF THE BOARD AND WHERE THE CONFLICT CONCERNS ANY BOARD OR COMMITTEE MEMBER, THE INDIVIDUAL(S) IS NOT PERMITTED TO PARTICIPATE IN ANY VOTE OR DELIBERATION ON THE MATTER NOR BE COUNTED IN DETERMINING THE EXISTENCE OF A QUORUM FOR THE PURPOSES OF ANY ACTION OF THE BOARD OR COMMITTEE CONSIDERING THE MATTER. THE ANNUAL DISCLOSURES BY STAFF ARE REVIEWED BY SENIOR MANAGEMENT. FORM 990, PART VI, SECTION B, LINES 13 AND 14 THE ORGANIZATION'S WRITTEN WHISTLEBLOWER AND DOCUMENT RETENTION AND DESTRUCTION POLICIES WERE DEVELOPED BY MANAGEMENT AND HAVE BEEN IN PLACE FOR SEVERAL YEARS. FORM 990, PART VI, SECTION B, LINES 15A AND 15B THE COMPENSATION OF THE MEMBERS OF THE BOARD OF DIRECTORS, THE EXECUTIVE OFFICERS, KEY EMPLOYEES AND FORMER DIRECTORS AND OFFICERS WHO ARE RETAINED AS EMPLOYEES/CONSULTANTS OF THE INSTITUTE IS SUBJECT TO REVIEW BY THE INSTITUTE'S BOARD COMPENSATION COMMITTEE. INDEPENDENT COMPENSATION CONSULTANTS PROVIDE COMPARABILITY SURVEYS TO THE COMMITTEE. MINUTES OF THE REVIEW, DECISIONS MADE AND RECOMMENDATIONS TO THE BOARD OF DIRECTORS BY THE COMPENSATION COMMITTEE DURING THE REVIEW ARE KEPT AND, ONCE APPROVED, ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. THE COMPENSATION COMMITTEE'S RECOMMENDATIONS TO THE BOARD OF DIRECTORS ARE THEN REVIEWED BY THE BOARD AND, IF APPROPRIATE, APPROVED BY THE BOARD. MINUTES OF ALL BOARD MEETINGS ARE KEPT AND, ONCE APPROVED, ARE SIGNED BY THE CHAIRPERSON AND THE SECRETARY TO THE BOARD. FORM 990, PART VI, SECTION C, LINE 19 THE INSTITUTE MAKES THE FOLLOWING DOCUMENTS AVAILABLE TO THE PUBLIC ON ITS COMPANY WEBSITE WWW.LICR.ORG: - LICR ANNUAL RESEARCH HIGHLIGHTS REPORT - LICR ORGANIZATION TAX EXEMPT FORM 990 AND - LICR ANNUAL REPORT. THE LICR ANNUAL REPORT INCLUDES THE STATUTORY FINANCIAL STATEMENTS OF THE INSTITUTE, WHICH HAVE BEEN PREPARED IN ACCORDANCE WITH THE PROVISIONS OF THE SWISS CODE OF OBLIGATIONS AND THE CONSOLIDATED FINANCIAL STATEMENTS OF THE INSTITUTE, WHICH HAVE BEEN PREPARED IN ACCORDANCE WITH SWISS-GAAP FER. GOVERNING DOCUMENTS AND THE CONFLICT OF INTEREST POLICY ARE AVAILABLE ON REQUEST AT THE ADMINISTRATIVE OFFICES IN NEW YORK AND ZURICH, SWITZERLAND. FORM 990, PART VII AS PART OF THE ANNUAL PREPARATION OF THE FORM 990, THE CHIEF FINANCIAL OFFICER ASKS ALL BOARD OF DIRECTORS AND EXECUTIVE OFFICERS FOR THEIR ESTIMATE OF HOURS WORKED FOR THE INSTITUTE AND THE RELATED ORGANIZATIONS. (SEE ATTACHMENT 2 FOR HOURS DEVOTED TO RELATED ORGANIZATIONS.) THE RELATED ORGANIZATIONS REPORT THE RESPECTIVE COMPENSATION FIGURES TO THE INSTITUTE AND PROVIDE COPIES OF THE SUBMITTED W-2 RETURNS/1099 RETURNS. FORM 990 , PART XI, LINE 5 FOREIGN EXCHANGE DIFFERENCE ON SHARE CAPITAL AND LEGAL RESERVE. | |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Edward a McDermott Jr TITLE:Director, President HOURS:25 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:John D Gordan III TITLE:Director HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Sir Derek Roberts TITLE:Director, vice chairman HOURS:3 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Alfred Berger TITLE:Director HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Olivier R E Dunant TITLE:Director HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:dr Adolf E Kammerer TITLE:Director HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:John Notter TITLE:Director,chairman of the board HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Professor Jane Royston TITLE:Director HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:professor samuel hellman TITLE:director HOURS:3 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:STEPHEN BOLLENBACH TITLE:DIRECTOR HOURS:2 |
| HOURS DEVOTED FOR RELATED ORGANIZATION | FORM 990 PART VII | NAME:Dr Lloyd J Old TITLE:Director UNTIL 7/1/09 HOURS:3 |
| Software ID: | |
| Software Version: |